SCHEMBL5715090

SCHEMBL5715090

O=C(Oc1ccc(N2C(=O)C3CCCCC3C2=O)cn1)N1CCN(c2ccccn2)CC1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 10/20 0.47
KDM4E B2RXH2 9/20 0.47
HSD17B10 Q99714 6/20 0.47
HTT P42858 1/20 0.46
HRH3 Q9Y5N1 2/20 0.46
CYP2C9 P11712 2/20 0.44
CYP2C19 P33261 2/20 0.44
CYP1A2 P05177 1/20 0.44
CYP3A4 P08684 1/20 0.44
TSHR P16473 1/20 0.44
MAPK1 P28482 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
CPT2 P23786 1/20 0.44
CPT1A P50416 1/20 0.44
HPGD P15428 2/20 0.43
GPR119 Q8TDV5 1/20 0.43
ADRB2 P07550 1/20 0.43
POLB P06746 1/20 0.42
MAPT P10636 1/20 0.42
L3MBTL1 Q9Y468 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5714905 0.86 ALDH1A1 (0.39) ALDH1A1HRH3MAPK1SMN1; SMN2HPGD
SCHEMBL5714870 0.86 HRH3 (0.46) ALDH1A1HRH3SMN1; SMN2HPGDGPR119
SCHEMBL5714872 0.86 TACR3 (0.41) ALDH1A1HRH3CYP2C19CYP1A2TSHR
SCHEMBL5714741 0.86 HRH3 (0.49) ALDH1A1KDM4EHSD17B10HRH3SMN1; SMN2
SCHEMBL5715200 0.85 HRH3 (0.46) ALDH1A1HRH3HPGDMEN1KMT2A
SCHEMBL5714711 0.84 KDM4E (0.48) ALDH1A1KDM4ECYP2C19TSHRMAPK1
SCHEMBL5715183 0.83 SMN1; SMN2 (0.52) KDM4EHTTHRH3CYP2C9CYP2C19
SCHEMBL5904319 0.83 KMT2A (0.41) ALDH1A1HRH3SMN1; SMN2HPGDGPR119
SCHEMBL5715222 0.83 THRB (0.46) ALDH1A1KDM4ECYP2C19L3MBTL1KMT2A
SCHEMBL5714854 0.81 THRB (0.41) ALDH1A1KDM4ECYP2C19L3MBTL1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060160819-A1 Substitued piperazine carbamates NOVO NORDISK A/S (DK) 2006-07-20 US claimed
EP-1636189-A1 1-ARYL-4-(ARYLOXYCARBONYL)-PIPERAZINE DERIVATIVES FOR USE AS INHIBITORS OF HORMONE SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2006-03-22 EP claimed
WO-2004111007-A1 1-ARYL-4-(ARYLOXYCARBONYL)-PIPERAZINE DERIVATIVES FOR USE AS INHIBITORS OF HORMONE SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2004-12-23 WO claimed
US-20060160819-A1 Substitued piperazine carbamates NOVO NORDISK A/S (DK) 2006-07-20 US disclosed
EP-1636189-A1 1-ARYL-4-(ARYLOXYCARBONYL)-PIPERAZINE DERIVATIVES FOR USE AS INHIBITORS OF HORMONE SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2006-03-22 EP disclosed
WO-2004111007-A1 1-ARYL-4-(ARYLOXYCARBONYL)-PIPERAZINE DERIVATIVES FOR USE AS INHIBITORS OF HORMONE SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2004-12-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060160819-A1 Substitued piperazine carbamates LIPE, PNLIP, LIPC ALDH1A1 1021/4885KDM4E 1353/4885HSD17B10 285/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.